Scope of sacubitril/valsartan eligibility after heart failure hospitalization: Findings from the GWTG-HF registry (get with the guidelines-heart failure)

Circulation

Volumn 135, Issue 21, 2017, Pages 2077-2080

  Parikh, Kishan S ^a,b   Lippmann, Steven J ^a   Greiner, Melissa ^a   Heidenreich, Paul A ^c   Yancy, Clyde W ^d   Fonarow, Gregg C ^e   Hernandez, Adrian F ^a,b  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Drugs; Heart failure

Indexed keywords

SACUBITRIL; VALSARTAN; AMINOBUTYRIC ACID DERIVATIVE; SACUBITRIL PLUS VALSARTAN; TETRAZOLE DERIVATIVE;

ARTICLE; CLINICAL OUTCOME; ESTIMATED GLOMERULAR FILTRATION RATE; FOOD AND DRUG ADMINISTRATION; HEALTH INSURANCE; HEART EJECTION FRACTION; HEART FAILURE; HOSPITALIZATION; HUMAN; MEDICAL SOCIETY; MEDICARE; POST HOC ANALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; AGED; FEMALE; MALE; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; REGISTER; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMINOBUTYRATES; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; REGISTRIES; TETRAZOLES; VALSARTAN;

EID: 85019669545     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.117.027773     Document Type: Article

References (5)

1. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and Committees. Angiotensinneprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993-1004. doi: 10.1056/NEJMoa1409077.
2. Hong Y, LaBresh KA. Overview of the American Heart Association "Get with the Guidelines" programs: Coronary heart disease, stroke, and heart failure. Crit Pathw Cardiol. 2006;5:179-186. doi: 10.1097/01.hpc.0000243588.00012.79.
3. Solomon SD, Claggett B, Desai AS, Packer M, Zile M, Swedberg K, Rouleau JL, Shi VC, Starling RC, Kozan Ö, Dukat A, Lefkowitz MP, McMurray JJ. Influence of ejection fraction on outcomes and efficacy of sacubitril/valsartan (LCZ696) in heart failure with reduced ejection fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial. Circ Heart Fail. 2016;9:e002744. doi: 10.1161/CIRCHEARTFAILURE.115.002744.
4. Simpson J, Jhund PS, Silva Cardoso J, Martinez F, Mosterd A, Ramires F, Rizkala AR, Senni M, Squire I, Gong J, Lefkowitz MP, Shi VC, Desai AS, Rouleau JL, Swedberg K, Zile MR, Mc- Murray JJ, Packer M, Solomon SD; PARADIGM-HF Investigators and Committees. Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: An analysis of mortality and morbidity in PARADIGMHF. J Am Coll Cardiol. 2015;66:2059-2071. doi: 10.1016/j. jacc.2015.08.878.
5. Desai AS, Claggett BL, Packer M, Zile MR, Rouleau JL, Swedberg K, Shi V, Lefkowitz M, Starling R, Teerlink J, McMurray JJ, Solomon SD; PARADIGM-HF Investigators. Influence of sacubitril/valsartan (LCZ696) on 30-day readmission after heart failure hospitalization. J Am Coll Cardiol. 2016;68:241-248. doi: 10.1016/j. jacc.2016.04.047.